Lamivudine and Zidovudine - Lamivudine and Zidovudine
Navigation: NDC > Supplier starting with: A > AVKARE, INC.| Field | Value |
|---|---|
| NDC Code: | 42291-363 |
| Proprietary Name: | Lamivudine and Zidovudine |
| Suffix: | |
| Non-Proprietary Name: | Lamivudine and Zidovudine |
| Dosage Form: | TABLET, FILM COATED |
| Method: | ORAL |
| Original Marketing Date: | 16-10-2013 |
| Category Name: | ANDA |
| Application Number: | ANDA079081 |
| Labeler: | AVKARE, INC. |
| Substance Name: | LAMIVUDINE; ZIDOVUDINE |
| Active Numerator Strength: | 150; 300 |
| Active Ingredient Unit: | mg/1; mg/1 |
| Pharm Classes: | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
| DEA Schedule: |